Medical technology company Stryker (NYSE: SYK) met Wall Street’s revenue expectations in Q2 CY2026, with sales up 9.4% year on year to $6.59 billion. Its non-GAAP profit of $3.69 per share was 5.8% above analysts’ consensus estimates.
Is now the time to buy SYK? Find out in our full research report (it’s free for active Edge members).
Stryker (SYK) Q2 CY2026 Highlights:
- Revenue: $6.59 billion vs analyst estimates of $6.57 billion (9.4% year-on-year growth, in line)
- Adjusted EPS: $3.69 vs analyst estimates of $3.49 (5.8% beat)
- Management slightly raised its full-year Adjusted EPS guidance to $15.02 at the midpoint
- Operating Margin: 25.2%, up from 18.5% in the same quarter last year
- Organic Revenue rose 9% year on year (miss)
- Market Capitalization: $133.4 billion
StockStory’s Take
Stryker’s second quarter results met Wall Street’s revenue expectations, yet the market responded negatively, reflecting investor concerns about the company’s supply chain disruptions and their impact on near-term growth. Management identified ongoing backorders in the peripheral vascular business as a primary headwind, noting that while production is ramping up, these issues led to lost sales and an elevated backlog. CEO Kevin Lobo described the quarter as a period of recovery from a recent cybersecurity incident, emphasizing, “We delivered strong organic sales growth… [but] supply disruption resulted in a meaningful backorder situation with lost sales in the quarter.”
Looking forward, Stryker’s guidance is shaped by confidence in robust demand for capital equipment, a steady procedural environment, and the expectation that resolving supply chain challenges will support second-half growth. Management highlighted elevated backlog levels and strong orders as signs of durable demand, but acknowledged that production ramp-up and remediation of the vascular supply issue are key execution risks. CFO Preston Wells noted, “We are narrowing our full year guidance… driven by high demand for our capital products, continued production ramp, and strong commercial execution,” while cautioning that manufacturing and cybersecurity remediation costs will continue to affect margins.
Key Insights from Management’s Remarks
Management attributed second quarter performance to strong demand across most business lines, with operational setbacks in peripheral vascular supply and production recovery efforts following a cyber event.
- Peripheral vascular supply disruption: A significant supply chain issue in the peripheral vascular segment led to meaningful lost sales and elevated backorders, with management expecting backorders to normalize by the end of Q3.
- Recovery from cybersecurity incident: The company continued ramping production after a cyberattack earlier in the year, which had disrupted manufacturing but is now largely resolved, contributing to a high backlog and strong capital equipment demand.
- Mako robotics momentum: Stryker delivered its highest-ever Q2 for Mako robotic system installations, with increasing utilization rates and new product launches like Mako RPS broadening its robotics offering across joint replacement procedures.
- International and segment growth: Growth was broad-based internationally, particularly in Australia, Germany, Canada, South Korea, Japan, India, and Brazil, and strong U.S. performances in medical, trauma, extremities, and endoscopy businesses offsetting weakness in vascular.
- Margin expansion and cost management: Non-GAAP operating margin expanded, benefiting from operational discipline, a net tariff refund, and ongoing efficiency initiatives, though management flagged ongoing costs related to cybersecurity remediation and supply chain stabilization.
Drivers of Future Performance
Stryker’s updated full-year outlook relies on capitalizing on elevated demand for capital products, steady procedure trends, and overcoming operational headwinds from earlier disruptions.
- Capital equipment backlog realization: Management pointed to a substantial backlog in capital equipment orders, asserting that successful production ramp-up and fulfillment will be crucial for revenue acceleration in the second half.
- Peripheral vascular supply recovery: The pace at which Stryker resolves backorders and reestablishes peripheral vascular product availability is expected to significantly impact growth and customer relationships in upcoming quarters.
- Margin and expense pressures: While margin improvement is expected from ongoing operational efficiencies, the company faces cost pressures from cybersecurity remediation, increased production expenses, and raw material volatility, which could constrain profitability if not managed effectively.
Catalysts in Upcoming Quarters
Our analysts will closely monitor (1) Stryker’s progress in resolving peripheral vascular backorders and returning to normal supply levels, (2) the pace of capital equipment backlog conversion amid ongoing production ramp-up, and (3) execution on new product launches like Mako RPS and Sonopet 3 Ultrasonic Aspirator. Updates on cybersecurity remediation and related costs will also be key signposts for the company’s operational resilience.
Stryker currently trades at $321.25, down from $348.10 just before the earnings. In the wake of this quarter, is it a buy or sell? The answer lies in our full research report (it’s free).
High Quality Stocks for All Market Conditions
WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.
But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.
